• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物相关性颌骨坏死伴自发性半侧上颌骨脱落:一例接受多药治疗的转移性肾癌患者的病例报告

Medication-Related Osteonecrosis of the Jaw with Spontaneous Hemimaxilla Exfoliation: Report of a Case in Metastatic Renal Cancer Patient under Multidrug Therapy.

作者信息

Bennardo F, Buffone C, Muraca D, Antonelli A, Giudice A

机构信息

School of Dentistry, Department of Health Sciences, Magna Graecia University of Catanzaro, Viale Europa, Catanzaro 88100, Italy.

出版信息

Case Rep Med. 2020 Oct 22;2020:8093293. doi: 10.1155/2020/8093293. eCollection 2020.

DOI:10.1155/2020/8093293
PMID:33144863
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7599406/
Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a well-recognized complication of drug therapies for bone metabolic disorders or cancer related to administration of antiresorptive (bisphosphonates and denosumab) and antiangiogenic drugs. This report describes an advanced and unusual case of stage III peri-implantitis-induced MRONJ involving the right upper jaw which was attempting to self-exfoliate. A 61-year-old male patient, rehabilitated with the placement of two implants when he was still healthy, was suffering from metastatic renal cancer previously treated with bevacizumab, interleukin-2, zoledronic acid, denosumab, cabozantinib and nivolumab. He had been under treatment of nonsurgical therapy over a year, based on antibiotic and antiseptic mouth rinse, without improvement of oral conditions. Surgical treatment consisted of massive sequestrectomy and complete surgical debridement of necrotic bone tissues. The specimen was sent for histopathologic analysis, which confirmed bone tissue necrosis with no evidence of metastatic disease. Two-month follow-up revealed a considerable life quality improvement. Although this complication is well known, the uniqueness of this case is given by its severity, related to the administration of multiple antiresorptive and antiangiogenic drugs, by the natural response of the oral cavity with the almost complete self-exfoliation of the massive necrotic zone. This case is emblematic in highlighting the controversies in the management of MRONJ, which certainly require effective collaboration of the multidisciplinary health care team that could improve patient safety and reduce the risk of developing MRONJ.

摘要

药物相关性颌骨坏死(MRONJ)是用于治疗骨代谢紊乱或癌症的药物疗法的一种公认并发症,与抗吸收药物(双膦酸盐和地诺单抗)及抗血管生成药物的使用有关。本报告描述了一例晚期且不寻常的III期种植体周围炎诱发的MRONJ病例,累及右上颌,坏死骨块几乎完全自行脱落。一名61岁男性患者,在身体健康时植入了两颗种植体,此前患有转移性肾癌,接受过贝伐单抗、白细胞介素-2、唑来膦酸、地诺单抗、卡博替尼和纳武单抗治疗。他接受了一年多基于抗生素和防腐漱口水的非手术治疗,但口腔状况没有改善。手术治疗包括大块死骨切除术和对坏死骨组织进行彻底的外科清创。标本送去做组织病理学分析,结果证实为骨组织坏死,无转移性疾病证据。两个月的随访显示生活质量有显著改善。尽管这种并发症广为人知,但该病例的独特之处在于其严重性,这与多种抗吸收和抗血管生成药物的使用有关,还在于口腔的自然反应,即大块坏死区几乎完全自行脱落。该病例凸显了MRONJ治疗中的争议,这无疑需要多学科医疗团队的有效协作,以提高患者安全性并降低发生MRONJ的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/2cbde384e760/CRIM2020-8093293.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/63d5dd20aa7f/CRIM2020-8093293.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/d7484097d851/CRIM2020-8093293.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/d0f16b9fbe5a/CRIM2020-8093293.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/2cbde384e760/CRIM2020-8093293.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/63d5dd20aa7f/CRIM2020-8093293.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/d7484097d851/CRIM2020-8093293.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/d0f16b9fbe5a/CRIM2020-8093293.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38cc/7599406/2cbde384e760/CRIM2020-8093293.004.jpg

相似文献

1
Medication-Related Osteonecrosis of the Jaw with Spontaneous Hemimaxilla Exfoliation: Report of a Case in Metastatic Renal Cancer Patient under Multidrug Therapy.药物相关性颌骨坏死伴自发性半侧上颌骨脱落:一例接受多药治疗的转移性肾癌患者的病例报告
Case Rep Med. 2020 Oct 22;2020:8093293. doi: 10.1155/2020/8093293. eCollection 2020.
2
Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.接受非手术牙周治疗后发生的地舒单抗相关性颌骨坏死:病例报告。
J Clin Periodontol. 2018 May;45(5):570-577. doi: 10.1111/jcpe.12882. Epub 2018 Apr 16.
3
[Position paper on medication-related osteonecrosis of the jaw (MRONJ)].[关于药物性颌骨坏死(MRONJ)的立场文件]
Wien Med Wochenschr. 2016 Feb;166(1-2):68-74. doi: 10.1007/s10354-016-0437-2.
4
Osteonecrosis of the jaw associated with ziv-aflibercept.与阿柏西普相关的颌骨骨坏死
J Gastrointest Oncol. 2016 Dec;7(6):E81-E87. doi: 10.21037/jgo.2016.05.07.
5
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
6
Medication-related osteonecrosis of the jaw: Case series and literature review.药物相关性颌骨坏死:病例系列与文献综述
Clin Case Rep. 2024 Apr 20;12(4):e8788. doi: 10.1002/ccr3.8788. eCollection 2024 Apr.
7
Medication-Related Osteonecrosis of the Jaw: A Case Report of an Unusual Side Effect of Adalimumab.药物相关性颌骨坏死:一例阿达木单抗罕见副作用的病例报告
Case Rep Dent. 2023 Dec 15;2023:5544285. doi: 10.1155/2023/5544285. eCollection 2023.
8
A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants.1例罕见的与牙科种植体相关的贝伐单抗相关性颌骨坏死病例。
Int J Implant Dent. 2019 Oct 1;5(1):34. doi: 10.1186/s40729-019-0188-0.
9
Spontaneous Healing of Mandibular Noncontinuous Defect Caused by Medication-Related Osteonecrosis of the Jaw.药物相关性颌骨坏死所致下颌骨非连续性缺损的自发愈合
J Craniofac Surg. 2016 Jun;27(4):e390-2. doi: 10.1097/SCS.0000000000002665.
10
The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report.采用富含血小板的高级纤维蛋白(A-PRF)治疗药物相关性颌骨坏死(MRONJ):一例报告。
Clin Case Rep. 2023 Nov 25;11(11):e8259. doi: 10.1002/ccr3.8259. eCollection 2023 Nov.

引用本文的文献

1
Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series.药物相关性颌骨坏死:病例报告与病例系列的系统评价
Diseases. 2024 Sep 9;12(9):205. doi: 10.3390/diseases12090205.
2
Improvement of Quality of Life after Surgical Treatment of Patients with MRONJ: A Prospective Analysis Using the SF-12 and OHIP-14 Questionnaires.MRONJ患者手术治疗后生活质量的改善:使用SF - 12和OHIP - 14问卷的前瞻性分析
Int J Dent. 2024 Apr 30;2024:4435791. doi: 10.1155/2024/4435791. eCollection 2024.
3
Peri-implantitis increases the risk of medication-related osteonecrosis of the jaws associated with osseointegrated implants in rats treated with zoledronate.

本文引用的文献

1
Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review.血小板浓缩物在预防和治疗药物相关性颌骨坏死中的应用是否有效?系统评价。
J Craniomaxillofac Surg. 2020 Mar;48(3):268-285. doi: 10.1016/j.jcms.2020.01.014. Epub 2020 Feb 3.
2
Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges.欧洲颌骨药物性骨坏死特别工作组研讨会——当前挑战
Oral Dis. 2019 Oct;25(7):1815-1821. doi: 10.1111/odi.13160. Epub 2019 Aug 19.
3
Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw.
种植体周炎增加了接受唑来膦酸盐治疗的大鼠中与骨整合种植体相关的药物相关性颌骨坏死的风险。
Sci Rep. 2024 Jan 5;14(1):627. doi: 10.1038/s41598-023-49647-4.
4
Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention.免疫检查点抑制剂所致颌骨骨坏死:亟需关注
J Transl Med. 2023 Sep 5;21(1):592. doi: 10.1186/s12967-023-04482-z.
5
Oral Health-Related Quality of Life and Mental Health Impairment in Patients Affected by Medication-Related Osteonecrosis of the Jaws: A Case-Control Pilot Study.药物性颌骨坏死患者的口腔健康相关生活质量与心理健康损害:一项病例对照试点研究。
Dent J (Basel). 2023 Jun 7;11(6):147. doi: 10.3390/dj11060147.
6
Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma.医学治疗对晚期肾细胞癌骨代谢的影响
Cancers (Basel). 2023 Jan 15;15(2):529. doi: 10.3390/cancers15020529.
7
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.颌骨坏死:甲状腺癌患者接受酪氨酸激酶抑制剂和双膦酸盐治疗的罕见但可能出现的副作用。
J Endocrinol Invest. 2021 Dec;44(12):2557-2566. doi: 10.1007/s40618-021-01634-0. Epub 2021 Jul 21.
超声压电骨手术联合富含白细胞和血小板的纤维蛋白及带蒂颊脂垫瓣治疗地诺单抗相关颌骨骨坏死
J Craniofac Surg. 2019 Jul;30(5):e434-e436. doi: 10.1097/SCS.0000000000005472.
4
General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England.全科牙医对通过多学科方法预防药物相关性颌骨骨髓炎 (MRONJ) 来提高患者安全性的看法和态度:英格兰东北部的一项定性研究。
BMJ Open. 2019 Jun 17;9(6):e029951. doi: 10.1136/bmjopen-2019-029951.
5
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review.药物相关性颌骨骨坏死与双膦酸盐和地舒单抗无关——综述。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Apr;127(4):289-299. doi: 10.1016/j.oooo.2018.11.012. Epub 2018 Dec 3.
6
Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.药物相关性颌骨骨坏死的保守非手术治疗是否适用于早期阶段?一项长期的单中心队列研究。
J Craniomaxillofac Surg. 2019 Mar;47(3):491-499. doi: 10.1016/j.jcms.2018.12.014. Epub 2018 Dec 29.
7
Surgical treatment of medication-related osteonecrosis of the upper jaw: Case series.手术治疗药物相关性上颌骨骨坏死:病例系列。
Oral Dis. 2019 Mar;25(2):497-507. doi: 10.1111/odi.12992. Epub 2018 Nov 8.
8
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.当前对颌骨骨坏死病理生理学的认识。
Curr Osteoporos Rep. 2018 Oct;16(5):584-595. doi: 10.1007/s11914-018-0474-4.
9
Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study.富血小板纤维蛋白能否改善药物相关性颌骨骨坏死手术治疗后的愈合?一项初步研究。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Nov;126(5):390-403. doi: 10.1016/j.oooo.2018.06.007. Epub 2018 Jun 30.
10
Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.用地诺单抗替代唑来膦酸是发生颌骨坏死的一个危险因素。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):547-551. doi: 10.1016/j.oooo.2018.02.010. Epub 2018 Mar 6.